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The external globus pallidus (GP) is a key GABAergic
hub in the basal ganglia (BG) circuitry, a neuronal
network involved in motor control. In Parkinson’s
disease (PD), the rate and pattern of activity of
GP neurons are profoundly altered and contribute
to the motor symptoms of the disease. In rodent
models of PD, the striato-pallidal pathway is hyper-
active, and extracellular GABA concentrations are
abnormally elevated in the GP, supporting the hy-
pothesis of an alteration of neuronal and/or glial
clearance of GABA. Here, we discovered the exis-
tence of persistent GABAergic tonic inhibition in GP
neurons of dopamine-depleted (DD) rodent models.
We showed that glial GAT-3 transporters are down-
regulated while neuronal GAT-1 function remains
normal in DD rodents. Finally, we showed that block-
ing GAT-3 activity in vivo alters the motor coordina-
tion of control rodents, suggesting that GABAergic
tonic inhibition in the GP contributes to the patho-
physiology of PD.
INTRODUCTION
In the CNS, two forms of GABAergic inhibition coexist to control
the excitability of neuronal networks (Farrant and Nusser, 2005).
Fast, phasic synaptic transmission precisely regulates action
potential generation and synchronized activity among neurons
(Baufreton et al., 2005, 2009; Cobb et al., 1995), while persistent
tonic inhibition sets the global level of excitability of neurons
(Semyanov et al., 2004). Both phasic and tonic inhibition trans-
mission are precisely controlled by GABA transporters (GATs),
whose main functions are to rapidly remove GABA from the1678 Cell Reports 23, 1678–1690, May 8, 2018 ª 2018 The Author(s)
This is an open access article under the CC BY-NC-ND license (http://synaptic cleft, prevent GABA spillover to neighboring synapses
(Overstreet andWestbrook, 2003), and limit excessive activation
of synaptic and extrasynaptic GABA receptors (Brickley and
Mody, 2012). Three subtypes of GATs (GAT1–3) have been
identified among the neurotransmitter: sodium symporter family
(Scimemi, 2014b), with GAT-1 and GAT-3 expressed widely
throughout the brain (Ikegaki et al., 1994). Dysfunctions of
GAT-1 or GAT-3 are associated with several neurological disor-
ders, such as absence epilepsy (Cope et al., 2009), Alzheimer’s
disease (Wu et al., 2014), and strokes (Clarkson et al., 2010), but
not yet with Parkinson’s disease (PD) pathophysiology.
The basal ganglia (BG) are a collection of subcortical nuclei
implicated in motor planning, action selection (Albin et al.,
1989), and habit formation (Yin and Knowlton, 2006), and they
are also the major site of pathology and dysfunction in PD
following the progressive loss of substantia nigra dopamine-syn-
thesizing neurons (Hammond et al., 2007). The external globus
pallidus (GP) is a GABAergic nucleus composed of several sub-
types of projection neurons (Abdi et al., 2015; Dodson et al.,
2015; Herna´ndez et al., 2015; Mastro et al., 2014) that holds a
pivotal position in the circuit through its widespread projections
to all BG nuclei (Beier et al., 2017; Kita, 2007; Saunders et al.,
2016) and the cortex (Saunders et al., 2015). The activity of GP
neurons is controlled by extrinsic GABAergic inputs from striatal
indirect-pathway medium spiny neurons (iSPNs) and intrinsic
pallidal local collaterals (Miguelez et al., 2012; Rav-Acha et al.,
2005; Sims et al., 2008).
GAT-1 and GAT-3 are both expressed in the GP. GAT-1 is
predominantly found in axon terminals and glial processes
juxtaposed at symmetrical synapses, while GAT-3 is exclusively
located on glial processes (Galvan et al., 2005; Jin et al., 2011a;
Ng et al., 2000; Wang and Ong, 1999). They exert a powerful
regulation of pallidal GABAergic transmission, as pharmacolog-
ical blockade of GAT-1 and/or GAT-3 prolongs GABAA-medi-
ated synaptic currents and generates a persistent tonic inhibi-
tion in GP neurons ex vivo (Jin et al., 2011b) while it reduces.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Tonic GABA Inhibition Is Observed in GP Neurons Only in Dopamine-Depleted Rodents
(A) Representative voltage-clamp recording showing spontaneous GABAergic synaptic (sIPSC) transmission in GP neurons recorded in brain slices obtained
from a control rat (CTR, black trace) and a dopamine-depleted (DD) rat (red trace).
(B and C) Boxplots showing sIPSC frequency (B) and amplitude (C) for both groups (control, n = 11; DD, n = 15; non-significant, n.s., p > 0.05, MW-U test).
(D and E) Effect of GABAzine (GBZ) on the holding current of a GP neuron under control (D, black traces) and DD conditions (E, red traces). Dashed lines indicate
the median currents of all points used to measure shifts in the holding current. The shift in the holding current (DI) is also represented on all-point histogram
distributions with their corresponding Gaussian fits.
(F) Boxplots depicting the presence of a tonic current only in GP neurons of DD animals (control, n = 8; DD, n = 7; *p = 0.0085; MW-U test).
Whiskers of the boxplots represent 10–90th percentiles.the firing rate of pallidal neurons in awake monkeys (Galvan
et al., 2005). Indeed, the importance of maintaining a controlled
discharge of GP neurons is well illustrated in PD, in which GP
neurons become hypoactive and synchronized at beta-band
frequencies (Bevan et al., 2002; Mallet et al., 2008; Mastro
et al., 2017; Raz et al., 2000). This alteration of firing rate and
pattern is believed to be the consequence of (1) a reduced
cellular excitability, leading to reduced pacemaking in subpop-
ulations of GP neurons (Chan et al., 2011; Herna´ndez et al.,
2015); and (2) the hyperactivity of iSPNs (Kita and Kita, 2011;
Mallet et al., 2006; Sharott et al., 2017). Dopamine-depleted
(DD) rodents show morphological changes at striato-pallidal
synaptic terminals (Ingham et al., 1997), increased striato-pal-
lidal synaptic transmission (Cui et al., 2016), and GP astrocyto-
sis (Charron et al., 2014), supporting iSPN hyperactivity as well
as local synaptic dysfunctions. While these modifications can
account for the elevated extracellular concentrations of GABA
observed in the GP of the DD rodents (Galeffi et al., 2003;
Ochi et al., 2000), the underlying synaptic mechanism(s) re-
mains unknown. In this study, we used patch-clamp electro-physiology, biochemistry, and in vivo pharmacology in behaving
rodents to investigate the alteration of GABA uptake by GATs in
the GP of DD rodents.
RESULTS
Persistent Tonic GABAergic Inhibition Appears in GP
Neurons after Chronic Dopamine Depletion
According to the classical anatomo-functional model of the BG
network, the indirect pathway of the BG is hyperactive after
the degeneration of midbrain dopaminergic neurons of the sub-
stantia nigra pars compacta (SNc). The primary nucleus of the
indirect pathway affected by iSPN hyperactivity is the GP. To
characterize the alteration of GABAergic synaptic transmission
in GP neurons in DD conditions (Figure 1), induced by unilateral
injection of the neurotoxin 6-hydroxydopamine (6-OHDA) in
the medial forebrain bundle of rats and mice, only animals with
a severe dopamine depletion (>70% reduction in optical density
of tyrosine hydroxylase-positive fibers in the striatum) were
included in this study (Figure S1).Cell Reports 23, 1678–1690, May 8, 2018 1679
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Figure 2. GABA-Mediated Tonic Current Is Independent of Neuronal Activity
(A) Typical example traces of mIPSCs recorded in the presence of 0.5 mM TTX in GP neurons from control (black trace) and DD (red trace) rats.
(B and C) Boxplots depicting the absence of change in the frequency (B) and the amplitude (C) after dopamine depletion (control, n = 11; DD, n = 15; non-
significant, n.s., p > 0.05, MW-U test).
(D and E) Effect of GBZ on the holding current of a GP neuron under control (D, black traces) and DD conditions (E, red traces). Dashed lines indicate the median
currents of all points used to measure shifts in the holding current. The shift in the holding current (DI) under DD conditions can also be observed on Gaussian fits
of all-point histograms.
(F) Boxplots depicting that a tonic current is still present in TTX in GP neurons of DD animals (control, n = 15; DD, n = 12; *p = 0.001, MW-U test).
Whiskers of the boxplots represent 10–90th percentiles.We first recorded spontaneous GABAergic inhibitory postsyn-
aptic currents (IPSCs) received by GP neurons in voltage-clamp
mode in acute brain slices from control and DD rats. GABAA
IPSCs were recorded in the presence of 50 mM D-(-)-2-Amino-
5-phosphonopentanoic acid (APV), 20 mM 6,7-Dinitroquinoxa-
line-2,3-dione (DNQX), and 1 mM (2S)-3-[[(1S)-1-(3,4-Dichloro-
phenyl)ethyl]amino-2-hydroxypropyl](phenylmethyl)phosphinic
acid (CGP55845) to selectively block NMDA, AMPA, and GABAB
receptors, respectively. The frequency and amplitude of sponta-
neous inhibitory post-synaptic currents (sIPSCs) were not
affected by dopaminergic degeneration (Figures 1A–1C) as
previously reported (Miguelez et al., 2012). Unexpectedly, we
discovered that blocking GABAA extrasynaptic receptors with
20 mM of the selective GABAA competitive antagonist SR95531
(GABAzine [GBZ]) induced a shift in the holding current attribut-
able to tonically activated GABAA receptors only in GP neurons
recorded from DD rat slices, suggesting an increased extracel-
lular concentration of GABA (control, DI = 2 [0;4] pA, n = 8; DD,
DI = 16 [7;42] pA, n = 7; p = 0.0085, Mann-Whitney [MW]-U
test; Figures 1D–1F). Similar results were obtained from DD1680 Cell Reports 23, 1678–1690, May 8, 2018mice (control, DI = 0 [2;6] pA, n = 7; DD, DI = 13 [6;40] pA,
n = 10; p = 0.0446, MW-U test). This form of inhibition, known
as tonic inhibition, has only been seen in GP neurons of control
rats when researchers have pharmacologically blocked GABA
transporters using selective antagonists (Jin et al., 2011b).
Thus, our results suggest that GABAergic transmission is altered
in the GP following the chronic loss of dopamine.
Several reports in the literature support the hypothesis that
iSPNs are hyperactive in PD (Mallet et al., 2006; Sharott et al.,
2017), and this GABAergic input to the GP is believed to be
responsible for the aberrant rate and pattern of activity of GP
neurons (Abdi et al., 2015; Kita and Kita, 2011; Mallet et al.,
2006). To test if tonic inhibition results from an increase in
GABA release from putatively hyperactive striato-pallidal synap-
ses, we recorded quantal synaptic GABAergic transmission in
the presence of 0.5 mM tetrodotoxin (TTX) to block activity-
dependent GABAergic transmission.
Miniature IPSC (mIPSC) amplitude and frequency medians
were not statistically different between control and DD slices
(Figures 2A–2C). While action potential-independent synaptic
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Figure 3. Pallidal Tonic Inhibition Is Mediated by d-Containing Extrasynaptic GABAA Receptors that Are Activated by Elevated Levels of
Extracellular GABA
(A and B) Examples of the effect of 1 mM THIP (an agonist of d-containing GABAA receptors) on the holding current of GP neurons recorded from wild-type mice
(d+/+) (A) and knockout mice for the GABAA receptors d subunit (d
/) (B). Shifts in holding currents are represented by dashed lines in electrophysiological
recordings and by Gaussian fits in all-point histograms.
(C) Boxplots showing the lack of effect of THIP in d/ mice (d+/+, n = 10; d/, n = 7; p = 0.0217, MW-U test).
(D and E) Examples of the effect of 1 mM THIP on the holding current of GP neurons recorded from control (D) and DD (E) rat slices.
(F) Boxplots indicating that THIP causes a tonic current of similar magnitude in control and DD conditions (control, n = 6; DD, n = 6; p = 0.809, MW-U test),
suggesting that tonic inhibition is not due to an upregulation of d-containing GABAA receptors.
Whiskers of the boxplots represent 10–90th percentiles.transmission remained similar, a tonic current was still
observed in the presence of TTX in DD slices when GBZ was
bath applied to block GABAA receptors. In identical conditions,
no current was detectable in slices obtained from control
rats (Figures 2D–2F; control, DI = 0 [0;1.83] pA, n = 15; DD,
DI = 20 [2.44;30] pA, n = 12; p = 0.001, MW-U test). These
results support the conclusion that tonic inhibition in DD ani-
mals is independent of action potential-dependent synaptic
release of GABA, and, therefore, it is not directly related to
iSPN hyperactivity.
Tonic GABA Inhibition Is Mediated by Extrasynaptic
d Subunits Containing GABAA Receptors
In the CNS, tonic inhibition is mediated by GABAA receptors
composed of specific subunits, such as d, a4, a5, or a6 (Brickley
and Mody, 2012), which give these receptors a high affinity for
GABA, slow desensitization, and fast deactivation kinetics (Bian-
chi et al., 2001; Haas andMacdonald, 1999). In theGP, d, a4, anda5 subunits have been detected at the protein level (Pirker
et al., 2000; Schwarzer et al., 2001; Kultas-Ilinsky et al., 1998;
Waldvogel and Faull, 2015). As d and a4 are often associated
in extrasynaptic GABAA receptors, we investigated the presence
of d subunits in GP neurons using the d-selective superagonist
4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP) in wild-
type mice (d+/+) and d subunit knockout mice (d/). THIP was
applied at a concentration of 1 mM, which has been reported to
selectively activate d-containing GABAA receptors (Drasbek
et al., 2007; Meera et al., 2011), and GBZ was used to measure
the magnitude of the tonic current. THIP induced a tonic current
only in wild-type mice, but not in d/mice (Figures 3A–3C; d+/+,
DI = 16.5 [12;28] pA, n = 10; d/, DI = 0.6 [0;13] pA, n = 7;
p = 0.0217, MW-U test), suggesting that extrasynaptic GABAA
receptors have d subunits in GP neurons. We also analyzed the
properties of spontaneous IPSCs in slices from both d+/+ and
d/ mice, and we did not find any differences in the amplitude,
frequency, rise time, and decay time (Table S1), suggestingCell Reports 23, 1678–1690, May 8, 2018 1681
that d subunits do not participate in the composition of synaptic
GABAA receptors.
Dopamine depletion can induce an alteration in GABAA recep-
tor level of expression that could be responsible for the appear-
ance of tonic inhibition in the GP. To test if d subunits are overex-
pressed in theGP after 6-OHDA-induced destruction ofmidbrain
dopaminergic neurons, wemeasured themagnitude of the THIP-
induced currents in control and DD rats. No differences in the
magnitude of THIP-induced currents were found between the
two groups (Figures 3D–3F; control, DI = 27.25 [15;37] pA,
n = 6; DD, DI = 20 [13;41] pA, n = 6; p = 0.809, MW-U test), sug-
gesting that pallidal tonic inhibition is not due to d-containing
GABAA receptor overexpression in DD rats. THIP did not modify
the kinetics of sIPSCs (Table S2), excluding the presence of
GABAA d subunits in the composition of synaptic GABAA recep-
tors in GP neurons.
Finally, we tested the contribution of GABAA a5 subunits in
pallidal tonic inhibition using the a5 inverse agonist L655,708.
Perfusion of 1 mM L655,708 did not modify the holding current
in DD slices, suggesting that a5 subunits do not contribute to
tonic inhibition under dopamine-deprived conditions in GP neu-
rons (Figures S2A and S2B). Furthermore, themagnitude of tonic
current was also similar after the application of GBZ in the pres-
ence of L655,708 compared to GBZ alone in DD slices. L655,708
did not modify the kinetics of sIPSCs (Figures S2C–S2F),
excluding the presence of GABAA a5 subunits in the composition
of synaptic GABAA receptors in GP neurons.
Altogether, these results suggest that tonic inhibition in the
GP is mediated by d-containing extrasynaptic GABAA receptors
but does not rely on an overexpression of these receptors in
pathological conditions.
Tonic Inhibition Is Present in All Subtypes of GPNeurons
Several recent reports have shown that the GP is populated by
two main neuronal subtypes: prototypic and arkypallidal GP
neurons (Abdi et al., 2015; Dodson et al., 2015). Prototypic GP
neurons are characterized by the expression of PV and or
Nkx2.1, while arkypallidal GP neurons are devoid of these two
markers but selectively express FoxP2. We used PV::Ai9T and
Nkx2.1::Ai9T reporter mice to selectively record prototypic
(PV- and Nkx2.1-expressing neurons are labeled by the fluores-
cent protein dTomato in these mouse lines) and arkypallidal
(FoxP2-expressing neurons identified by post hoc immunohis-
tochemistry) GP neurons and test if tonic inhibition was present
in all these cell types. We artificially augmented extracellular
GABA concentrations by blocking GAT-1 transporters, and we
tested the effect of a saturating concentration of GBZ on the
holding current of prototypic PV-expressing and Nkx2.1-
expressing GP neurons. In these two subtypes of prototypic
GP neurons, a tonic current was detected (Figures S3A–S3H;
PV, DI = 12.81 [10.98;27] pA, n = 5; Nkx2.1, DI = 22.58
[8.54;37.84] pA, n = 9). The same experiment was performed
on arkypallidal neurons and also revealed tonic inhibition in
these neurons (Figures S3I–S3L; FoxP2, DI = 27.46 [0;43.94]
pA, n = 5). These results indicate that both GP neuron popula-
tions express extrasynaptic GABAA receptors responsible for
the tonic inhibition triggered by elevated extracellular GABA
concentrations.1682 Cell Reports 23, 1678–1690, May 8, 2018Reduced Expression of Glial GAT-3 Transporters Is
Responsible for Tonic GABA Inhibition in DD Rats
Extracellular GABA concentrations are tightly regulated by
neuronal and glial GABA transporters GAT-1 andGAT-3, respec-
tively. We first investigated GAT-1 function in control and DD
conditions in rats. In control slices, bath application of 10 mM
NNC711, a selective inhibitor of GAT-1, generated a tonic cur-
rent compared to the application of GBZ alone (Figures S4A–
S4C; GBZ, DI = 0 [0;9.8] pA, n = 9; NNC711 + GBZ, DI = 25;
[14;40] pA, n = 12; p = 0.0027,MW-U test). In DD slices, the appli-
cation of NNC711 produced a significantly greater current
compared to the application of GBZ alone (Figures S4D–S4F;
GBZ, DI = 15 [7;31] pA, n = 7; NNC711 + GBZ, DI = 36 [22;60]
pA, n = 11; p = 0.0459; MW-U test), suggesting that blocking
these neuronal transporters can exacerbate the tonic current
observed in basal conditions in DD rats. Nevertheless, the
amount of tonic inhibition due to GAT-1 in control and DD condi-
tions was of similar magnitude, which suggests that GAT-1
transport is not altered in DD rats. GAT-1 blockade did not affect
IPSC kinetics (Table S3), which suggests that, under basal syn-
aptic transmission, GAT-1 contributes little to the regulation of
synaptic GABAA receptor currents in GP neurons. In addition,
GABA uptake experiments performed from punches of the
GP revealed that GAT-1 transporters tended to uptake GABA
more efficiently in DD conditions (Figures S4G–S4I). This better
efficiency is attributable to a greater maximal speed (Vmax)
of GABA uptake (control, Vmax = 1.67 3 106 [1.56 3
106;2.32 3 106] CPM/mg, n = 3; DD, Vmax = 3.88 3 106
[2.85 3 106;4.48 3 106] CPM/mg, n = 4; p = 0.057).
GAT-3 transporters contribute to GABA clearance from
GABAergic synapses, but they can also be a source of GABA
release when they function in a reverse transport mode (Sci-
memi, 2014a). To determine the mode of transport of GAT-3 in
the GP, we pharmacologically blocked GAT-3 in control and
DD slices. In control slices, GAT-3 limits extrasynaptic GABAA
receptor activation, as the GAT-3 selective antagonist SNAP-
5114 (20 mM) induced a tonic current in GP neurons; this result
is in agreement with a recent report (Jin et al., 2011b). This tonic
current was significantly greater than in control conditions (Fig-
ures 4A–4C; GBZ, DI = 0 [0;4] pA, n = 14; SNAP-5114 + GBZ,
DI = 16 [3;27] pA, n = 14; p = 0.0022, MW-U test). In contrast,
the same pharmacological treatment failed to increase tonic cur-
rent in GP neurons recorded from DD animals (Figures 4D–4F;
GBZ, DI = 20 [15;30.5] pA, n = 7; SNAP-5114 + GBZ, DI = 12.8
[11.6;20] pA, n = 7; p = 0.816, MW-U test), suggesting that
GAT-3 function was altered by chronic dopamine depletion. As
with GAT-1, GAT-3 blockade did not affect spontaneous IPSC
kinetics (Table S4), suggesting that, under basal synaptic trans-
mission, GAT-3 also contributes little to shape synaptic GABAA
receptor currents in GP neurons. Western blot experiments
with anti-GAT-3 antibodies revealed that GAT-3 expression
was significantly reduced by approximately 30% in GP punches
obtained from DD animals compared to control GP punches
(Figures 4G and 4H; control, GAT-3/Actin = 1.02 [0.857;1.077],
n = 11; DD, GAT-3/Actin = 0.70 [0.633;0.911], n = 7;
p = 0.0289, MW-U test). These results support the conclusion
that tonic inhibition is due to a down-expression of GAT-3, pre-
sumably located on astrocytes, in the GP of DD rodents.
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Figure 4. Pallidal Tonic Inhibition Results from a Reduced Expression of GAT-3 in DD Rats
(A andB) Representative voltage-clamp traces with their correspondingGaussian fits of all-point histograms recorded in the presence of 20 mMGBZ alone (A) and
in the presence of GBZ in combination with 20 mM SNAP-5114, a selective blocker of the GABA transporter GAT-3 (B).
(C) Boxplots showing that the blockade of GAT-3 significantly increases the magnitude of tonic inhibition in control animals (control, n = 14; DD, n = 14;
*p = 0.0022, MW-U test).
(D and E) (D) is the same as (A) and (E) is the same as (B) in DD slices.
(F) Boxplots indicating that the blockade of GAT-3 does not significantly increase the tonic inhibition in DD conditions (control, n = 8; DD, n = 7; p = 0.405,
MW-U test).
(G) Western blot showing the significant reduction in GAT-3 expression in DD conditions.
(H) Summary graph highlighting the significant reduction of GAT-3 protein expression in DD rats (control, n = 11; DD, n = 7; *p = 0.0289, MW-U test).
Whiskers of the boxplots represent 10–90th percentiles.To confirm the loss of function of GAT-3 in GP astrocytes, we
directly measured GAT-3 activity by recording the current gener-
ated by GABA uptake. GP astrocytes were initially identified on
the basis of their size and morphology (Figure 5A), followed by
their electrophysiological properties, which included linear I-V
relationship (Figure 5B), low input resistance (Figure 5C; control,Rm=33.49 [28.04; 41.48]MU, n = 18), and hyperpolarized resting
membrane potential (Figure 5D; control, Vm = 71.94 [75.29;
70.01] mV, n = 17). We did not find any modification in the I/V
curve (Figure 5B), membrane resistance (DD, Rm = 38.85
[34.35;73.06] MU, n = 15; p = 0.143, MW-U test), and resting
membrane potential (DD, Vm = 75 [77.6;68.72] mV, n = 15;Cell Reports 23, 1678–1690, May 8, 2018 1683
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Figure 5. GAT-3 Currents Are Reduced in GP Astrocytes of DD Rats
(A) Differential interference contrast (DIC) image of a GP astrocyte with a visible recording patch pipette.
(B) Current-voltage relationship of control (black) and DD (red) GP astrocytes obtained in response to 10-mV voltage steps.
(C) Boxplot representing GP astrocyte membrane resistance (control, n = 18; DD, n = 15; p = 0.1431, MW-U test).
(D) Boxplot depicting GP astrocyte membrane resting potential (control, n = 17; DD, n = 15; p = 0.597, MW-U test).
(E) Schematic diagram illustrating the experimental design for astrocyte GAT-3 current measurements.
(F) Typical responses of GP astrocytes to focal application of ACSF (top traces) and 10 mM GABA (middle traces) in the absence (black/red) and presence of
GAT-3 blocker (SNAP-5114, 20 mM; gray traces). The bottom traces represent the GAT-3 current obtained by subtracting the trace obtained by GABA puff alone
from the one in the presence of SNAP-5114.
(G) Boxplots showing a significant reduction in the amplitude of GAT-3 currents in GP astrocytes fromDD rats (control, n = 18; DD, n = 18; *p = 0.0022,MW-U test).
Whiskers of the boxplots represent 10–90th percentiles.p = 0.597, MW-U test) of GP astrocytes recorded from DD
compared to control animals, which is in agreement with a recent
report (Cui et al., 2016).
To isolate GAT-3-mediated currents, we added the GABAA
and GABAB receptor blockers GBZ (20 mM) and CGP55845
(1 mM), respectively, and the GAT-1 transporter blocker
NNC711 (10 mM) and TTX (0.5 mM) to the perfusion solution. Un-
der these experimental conditions, pressure puffs of GABA
(150 ms; 10 mM) evoked GAT-3-mediated currents in GP astro-
cyte plasma membranes during GABA uptake (Figure 5E).
GABA, but not artificial cerebro-spinal fluid (ACSF) puffs, gener-
ated inward currents that were abolished by 20 mM SNAP-5114,
indicating that these currents were mediated during GABA up-
take by GAT-3 (Figure 5F). Consistent with the decreased
expression of GAT-3 in the GP of DD rats, as measured by west-
ern blot analysis, the GAT-3 current amplitude was reduced by
60% in DD rats (Figure 5G; control, iGAT-3 = 60.97 [31;92.2]1684 Cell Reports 23, 1678–1690, May 8, 2018pA, n = 18; DD, iGAT-3 = 25 [10.2;43.5] pA, n = 18; p = 0.0013,
MW-U test), which strongly supports the conclusion that tonic
inhibition observed in GP neurons fromDD rats is due to reduced
expression of GAT-3 transporters in GP astrocytes.
It has been recently reported that GP astrocytes express D2
dopamine receptors (Cui et al., 2016). Therefore, it is possible
that dopamine regulates ambient GABA levels by controlling
GAT-3 activity or addressing at the plasma membrane. To test
this hypothesis, we artificially increased extracellular GABA con-
centration by applying 2 mMGABA in the superfusion to generate
tonic inhibition in GP neurons. To avoid the contribution of GAT-1
in GABA uptake, the recordings were done in the presence of
10 mM NNC711. Addition of the D2 receptor agonist quinpirole
(2 mM) induced a significant positive shift of the holding current,
suggesting that D2 receptor activation boosts GABA uptake by
GAT-3 in GP astrocytes (Figures 6A and 6C; n = 6). The effect
of quinpirole was completely occluded when it was applied in
A B C
Figure 6. GAT-3 Activity Is Regulated by D2 Dopamine Receptors
(A) Representative voltage-clamp traces with their corresponding Gaussian fits of all-point histograms recorded in the presence of 2 mM GABA and 10 mM
NNC711 to artificially elevate extracellular GABA concentrations and block GAT-1 activity, respectively. The addition of 2 mM quinpirole (Quin), a selective D2
dopamine receptor agonist, induced a shift in holding current.
(B) Same as (A) but in combination with 20 mM SNAP-5114, a selective blocker of the GABA transporter GAT-3. Note the absence of change in holding current.
(C) Boxplots indicating that quinpirole action of holding current is dependent onGAT-3 activity and is selective of D2 dopamine receptors, as its action is occluded
by the blockade of GAT-3 or by sulpiride (a D2 receptor selective antagonist), respectively (Quin, n = 6; Quin + SNAP, n = 6; Quin + Sulp, n = 4; p = 0.0049, Kruskal-
Wallis test). These experiments were performed in the presence of 50 mMAPV, 20 mMDNQX, and 1 mMCGP55845 to block NMDA, AMPA, and GABAB receptors,
respectively.
Whiskers of the boxplots represent 10–90th percentiles.either the presence of the GAT-3 antagonist SNAP-5114 (20 mM)
or the D2 dopamine receptor antagonist sulpiride (2 mM), sup-
porting the conclusion that the action of quinpirole on GP neu-
ron’s holding current is selective of D2 dopamine receptors
and dependent on GAT-3 activity (Figures 6B and 6C). Further
experiments will be required to determine if D2 dopamine recep-
tors control the membrane expression or the transport efficacy
of GAT-3 in the GP.
Intrapallidal GAT-3 Blockage Worsens Motor
Coordination in Control Animals
To address the functional role of GP GAT-3 transporters in vivo,
we administered SNAP-5114 intrapallidally (Figures 7A and 7B),
andwe evaluatedmotor behavior in control and DD rats. We per-
formed two types of behavioral tests: rotarod and cylinder tests.
The former evaluates coordination and balance during motor
execution and the latter measures forelimb asymmetry during
volunteer exploration.
To determine the dose of SNAP-5114 to use in the following
experiments, we first unilaterally injected five rats with vehicle
and seven animals with 2 mM, 2 mM, and 20 mM SNAP-5114
in the GP, and we tested their motor performance using the
rotarod. The rotarod was performed in the same animals, which
were tested with different doses every 4 days. From all doses
tested, the largest one, 20mM, produced a significant worsening
in motor coordination compared to those animals injected
with the vehicle (p < 0.001, Fisher’s least significant difference
[LSD] post hoc test).
In the following set of experiments, the intrapallidal administra-
tion of 20 mM SNAP-5114 was tested in consecutive days. As
shown in Figure 7C, 20 mM SNAP-5114 resulted in significantlyworsemotor performance in the rotarod from the first day of drug
administration (interaction factor: F(2,36) = 3.2, p = 0.05; treatment
factor: F(2,36) = 4.7, p = 0.04; repeated-measure [RM] two-way
ANOVA). SNAP-5114 did not produce forelimb asymmetry in
the animals evaluated in the cylinder test (Figure 7D) (interaction
factor: F(2,36) = 0.07, p = 0.92; treatment factor: F(2,36) = 0.32,
p = 0.72; RM two-way ANOVA). These behavioral data support
the conclusion that GP GAT-3 is essential for normal motor
coordination.
We also tested the effect of GAT-3 blockade in DD rats. In this
case, SNAP 5114 had no negative effect on rotarod performance
(Figure 7E; interaction factor: F(2,32) = 0.34, p = 0.714; treatment
factor: F(2,32) = 2.70, p = 0.08; RM two-way ANOVA) or in forelimb
asymmetry, evaluated with the cylinder test (Figure 7F; interac-
tion factor: F(2,32) = 1.84, p = 0.17; treatment factor: F(2,32) =
1.64, p = 0.21; RM two-way ANOVA). These results agree with
our findings that GAT-3 is impaired in DD conditions and, there-
fore, blockage of the glial GABA transporter does not worsen
motor coordination.
One limitation of the present study is the high concentration of
SNAP-5114 used in the behavioral experiments, which could
lead to the blockage of GAT-1 in addition to GAT-3. However,
the lack of effect of SNAP-5114 in DD rats confirms the specific
GAT-3 effect mediated by the drug in these experiments.
DISCUSSION
Using a combination of electrophysiological and biochemical
approaches, we show that chronic dopamine depletion in
rodents triggers the development of a tonic form of GABAergic
inhibition in the GP. Our data demonstrate that the synapticCell Reports 23, 1678–1690, May 8, 2018 1685
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Figure 7. Intrapallidal GAT-3 Blockage Impairs Motor Coordination in Control Rats
(A) Micrograph showing cannula emplacement in the GP taken for a control rat.
(B) Cannula placements in the GP for the control (n = 20) and DD (n = 18) groups. Each circle represents the position of one cannula for a given animal.
(C) Motor coordination and balance were evaluated in the rotarod for 3 consecutive days. The first day, the animals did not receive any drug; the second and third
days, animals received either 20 mM SNAP-5114 or vehicle. Animals treated with 20 mM SNAP showed significant impairment after drug administration.
(D) The same animals were also tested in the cylinder test but the drug produced no forelimb asymmetry. n = 10 rats in each group. *p < 0.05 and **p < 0.01 versus
respective vehicle group; ##p < 0.01 versus respective basal group, Fisher’s LSD post hoc test.
(E and F) (E) is the same as (C) and (F) is the same as (D) in DD rats. n = 9 DD rats in each group.
Whiskers of the boxplots represent 10–90th percentiles.mechanism responsible for this aberrant tonic inhibition is a
downregulation of GAT-3 in GP astrocytes. Finally, we show
that GP GAT-3 blockade impairs motor coordination in control
rats, highlighting the instrumental role played by this GABA
transporter in GP motor functions. Altogether, our study sug-
gests that GAT-3 dysfunction is associated with and may
contribute to the pathophysiology of PD.
The Nature of Extrasynaptic GABAA Receptors Involved
in Tonic Inhibition in GP Neurons
In the CNS, tonic inhibition is mediated by extrasynaptic GABAA
receptors composed of particular subunits that confer high affin-
ity for GABA and slow deactivation and desensitization kinetics.
These receptors most often contain a4, a5, a6, or d GABAA sub-
units. In the GP, the presence of a5 and d subunits is controver-
sial due to the low level of protein expression compared to the
striatum (Pirker et al., 2000; Schwarzer et al., 2001; Waldvogel
and Faull, 2015). We combined pharmacological experiments
with d/ mice to test for the involvement of this subunit in the
extrasynaptic receptors present in GP neurons. Our results sug-
gest that d-containing GABAA receptors are expressed in control
animals but are not activated under basal conditions whenGABA
transporters are functional. Furthermore, no tonic currents were
detectable in d/ mice, suggesting that the presence of this1686 Cell Reports 23, 1678–1690, May 8, 2018subunit is mandatory to have functional extrasynaptic GABAA re-
ceptors in GP neurons. Our results also show that the d-selective
drug THIP induced tonic currents of similar magnitude in both
control and DD animals, which excludes an increased expres-
sion of d subunits following chronic dopamine depletion. We
also tested the contribution of a5 subunits, which significantly
contribute to tonic inhibition in the striatum (Ade et al., 2008), cor-
tex (Clarkson et al., 2010), and hippocampus (Wu et al., 2014). In
contrast with previous results in those brain areas, the inverse
agonist L655,708 failed to modify the holding current in GP neu-
rons of DD rats, which excludes de novo expression of this sub-
unit in the GP following dopamine depletion.
The GP is composed of several neuronal populations with
embryonic, molecular, and functional specifications (Abdi
et al., 2015; Dodson et al., 2015; Herna´ndez et al., 2015; Mastro
et al., 2014; No´brega-Pereira et al., 2010). Two main cell popula-
tions, prototypic and arkypallidal neurons, have been identified
(Abdi et al., 2015; Dodson et al., 2015; Hegeman et al., 2016;
Mallet et al., 2012). All prototypic neurons express the tran-
scription factor (TF) Nkx2.1, and a great majority (70%) co-
expresses the calcium-binding protein parvalbumin, while arky-
pallidal neurons selectively express the TF FoxP2. While we
observed tonic inhibition inmost of our recordings of unidentified
GP neurons in DD rodents, we also demonstrated that both
prototypic (Nkx2.1 and PV positive) and arkypallidal neurons
(FoxP2 positive) were equipped with extrasynaptic receptors,
which suggests that DD-induced tonic inhibition is present in
all pallidal neuronal populations and, thus, affects the entire GP.
Tonic Inhibition in GP Neurons Is Independent of iSPN
Overactivity
According to the classical BG model (Albin et al., 1989) and
experimental data (Kita and Kita, 2011; Mallet et al., 2006; Shar-
ott et al., 2017), iSPNs become hyperactive following dopamine
deprivation. It has been shown that striato-pallidal synapses are
enlarged (Ingham et al., 1997) and striato-pallidal transmission is
overactive (Cui et al., 2016) in DD rodents. This hyperactivity
could result in GABA spillover from striato-pallidal synapses
and the activation of extrasynaptic GABAA receptors, meaning
that pallidal tonic inhibition could simply be the consequence
of the hyperactivity of the striato-pallidal connection. Our data
do not support this hypothesis, as tonic inhibition was still pre-
sent in the GP neurons of DD slices when recordings were per-
formed in the presence of TTX, which abolishes activity-depen-
dent synaptic release and significantly reduces synaptically
released GABA. This finding implies that pallidal tonic inhibition
is independent of iSPN hyperactivity and instead involves local
modifications at the level of pallidal GABAergic synapses.
Astrocytic GAT-3 Dysfunction Is Responsible for Tonic
Inhibition in GP Neurons
GATs represent the main buffering system to control extracel-
lular levels of GABA and to shape GABAergic transmission (Sci-
memi, 2014b). In the GP, extracellular GABA concentrations are
abnormally elevated in the DD condition (Galeffi et al., 2003; Ochi
et al., 2000), suggesting that GABA uptake is deficient. Electron
microscopy analysis has shown that GAT-1 is present in unmy-
elinated axons as well as in GP glial processes (Galvan et al.,
2005, 2010). Contrary to the thalamus, where down-expression
and reduced activity of GAT-1 are responsible for excessive
tonic inhibition in absence epilepsy (Cope et al., 2009; Errington
et al., 2011; Pirttimaki et al., 2013), in the GP we found that GAT-
1-mediated GABA uptake was not affected by DD. This result is
in agreement with anatomical data showing that GAT-1 expres-
sion and subcellular location are not affected in rodent and pri-
mate models of PD (Galvan et al., 2010).
GAT-3 is found exclusively in glial processes that ensheath
dendrites and terminals in the GP (Galvan et al., 2005; Ng
et al., 2000), suggesting that pallidal astrocytes actively
contribute to the regulation of GABA levels in the GP. GAT-3 pro-
vides an additional source of GABA through reverse transport in
the striatum and the hippocampus under several physiological
and pathological conditions (Allen et al., 2004; Wo´jtowicz et al.,
2013; Wu et al., 2007, 2014). In agreement with another study
(Jin et al., 2011b), we found that pharmacological blockade of
GAT-3 induced a significant GABAA-mediated tonic current in
dopamine (DA)-intact rodents, indicating that, under physiolog-
ical conditions, GAT-3 works in the uptake mode and removes
GABA from the synaptic cleft. Under the DD condition, the level
of tonic inhibition was not significantly modified by GAT-3 inhibi-
tion, which suggests that GAT-3 does not work in reverse mode
in PD, and that its functioning is altered in the GP. Using westernblot analysis, we demonstrated that GAT-3 expression was
indeed reduced by30% in the GP of DD animals. Furthermore,
direct recording of the currents generated during GABA uptake
by GAT-3 in GP astrocytes conclusively proved a reduced activ-
ity indicative of a loss of function. GAT-1 has been suggested
to prevent GABA escape from the synaptic cleft during phasic
synaptic transmission, while GAT-3 could be responsible for
controlling the ambient GABA concentration that mediates tonic
inhibition (Beenhakker and Huguenard, 2009). If this is the case
in the GP, it could explain why down-expression of GAT-3 is
not compensated by the apparent increase uptake activity of
GAT-1 we observed in DD conditions.
Other factors can contribute to the deficit of GABA uptake by
GAT-3, such as maladaptive structural plasticity or the alteration
of GAT-3 trafficking to astrocyte plasma membranes. Structural
plasticity has been observed in GP astrocytes during running ac-
tivity (Tatsumi et al., 2016), which suggests that they actively
contribute to motor functions. We recently showed that astrocy-
tosis takes place in the GP in response to chronic dopamine loss
(Charron et al., 2014), which suggests thatmaladaptive structural
plasticity of the tri-partite synapse, such as astrocyte processes
retraction, could also contribute toGAT-3deficiencyby removing
the transporters from GABAergic terminals. Only a few signaling
pathways regulatingGAT-3 have been described in the literature.
Among them,metabotropic ATPandadenosine receptors aswell
as TRPA1 channels are known to modulate GABA transport by
GAT-3 into the astrocytes (Cristo´v~ao-Ferreira et al., 2013; Jacob
et al., 2014;Shigetomi et al., 2011). In our study,we report a direct
modulation of GAT-3 activity byD2 dopamine receptors. It will be
interesting to investigate in more detail the signaling pathway
involved in this modulation of GAT-3 activity.
Functional Considerations
Balanced GABAergic inhibition in the GP is essential for proper
motor control. Artificial elevation of GABAergic transmission
by the pharmacological inhibition of GATs induces a reduction
of GP neuron firing discharge in awake DA-intact monkeys (Gal-
van et al., 2005, 2010), which somehow mimics the hypoactivity
observed in PD. On the other hand, blocking GABAA receptors in
DD rodents increases GP neuron activity and produces marked
antiparkinsonian effects (Maneuf et al., 1994; Xue et al., 2010). As
no specific agonist or positive modulator of GAT-3 is currently
available, we inhibited GAT-3 using microinjections of the selec-
tive antagonist SNAP-5114 in the GP of DA-intact rats, and we
found that, while forelimb akinesia was intact, motor coordina-
tion was significantly worse compared to vehicle-injected rats.
The same experiments in DD rats had no impact on motor
coordination, which is in line with the impairment of GAT-3
confirmed by electrophysiological and molecular approaches.
These results unambiguously demonstrate the importance of
GAT-3 in preventing excessive GABAergic inhibition and main-
taining the role in motor function played by the GP. As overac-
tivity of GABAergic signaling in the GP is one of the cardinal hall-
marks of PD (DeLong, 1990), the development of novel agonists
or positive modulators of GAT-3 appears to be a promising
therapeutic avenue to alleviate motor symptoms in PD.
In conclusion, GAT-3 downregulation/malfunction in the GP
is responsible for the persistent tonic inhibition observed in thisCell Reports 23, 1678–1690, May 8, 2018 1687
nucleus in models of PD. This modification could contribute to
the appearance of some of the motor symptoms that charac-
terize rodent PD models, and it also may have clinical conse-
quences in PD patients.EXPERIMENTAL PROCEDURES
All experiments were performed in agreement with the Bordeaux University
ethical committee (agreement A5012075) and are in compliance with Euro-
pean Economic Community guidelines (86/6091EEC). Sprague-Dawley rats
and C57BL6/J mice received a unilateral injection of 6-OHDA into the medial
forebrain bundle to lesion the nigrostriatal dopaminergic system.
Rat and mice of either sex were used for ex vivo experiments. Whole-cell
voltage- and current-clamp recordings of GP neurons and astrocytes were
performed on acute brain slices on a Nikon Eclipse workstation equipped
with a 603 water-immersion objective. Tonic inhibition was measured as a
shift in holding current induced by bath application of GBZ, a selective
GABAA receptor antagonist. Standard procedures were used to perform
immunohistochemistry and GAT-3 western blot experiments. Motor asymme-
try and motor coordination in 6-OHDA rats were assessed using rotarod and
cylinder tests.
Data analyses were done using ClampFit 9.2, Mini Detection 8.0 (in-house
software), Origin 7, and ImageJ. Data in the text are presented as median and
interquartile range. Boxplots with individual data points were used for graphic
representation. Wilcoxon signed-rank (WSR), MW-U, and Kruskal-Wallis tests
were used for statistical comparisons in ex vivo experiments. For behavior
experiments, repeated-measure two-way ANOVA followed by Fisher’s LSD
post hoc test were used. Data were considered significant at p < 0.05.
Mouse lines, reagents, and pharmacological tool details are provided in
Table S5.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and five tables and can be found with this article online at
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